MedTrace Logo

A Safety Study of Oral ZSTK474 in Patients With Cancer

NCT01280487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2015-01-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.

Conditions

  • Neoplasms

Interventions

DRUG

ZSTK474

Daily oral dosing for 21 days each cycle

Sponsors & Collaborators

  • Zenyaku Kogyo Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Craig Lockhart, MD · Washington University School of Medicine

  • Anthony Olszanski, MD · Fox Chase Cancer Center

  • Geoffrey Shapiro, MD PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280487 on ClinicalTrials.gov